Products and
Pipeline – TAK-102

Overview

Autologous T cells are transduced with a GPC3-targeting CAR gene and the genes that encode for IL-7 and CCL19^1-3

Mechanism of Action³

The design of this novel CAR T therapy has the potential to:

- Cause direct cytotoxicity mediated by GPC3-targeting CAR T cells

- Provide an armoring effect on CAR T cells through IL-7 and CCL19 production

TAK-102 is an investigational therapy. Clinical efficacy and safety have not yet been established.

APC, antigen-presenting cell; CAR, chimeric antigen receptor; CCL19, chemokine ligand 19; GPC3, glypican 3; IL-7, interferon 7.

Clinical Trials

Study Name

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors (This study is only recruiting in Japan)

References

1. An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors. Clinicaltrials.gov identifier: NCT04405778. Accessed April 2023. Web Link

2. Noile-Immune Biotech News release (Sep 11, 2020). Initiation of Phase I Clinical Trial of NIB-102/TAK-102. Available at: Web Link Accessed April 2023.

3. Noile-Immune Biotech. PRIME technology. Available at: Web Link Accessed April 2023.

Disclaimers

*Collaboration with Noile-Immune Biotech.